Black Diamond Therapeutics Inc [NASDAQ: BDTX] price surged by 19.69 percent to reach at $0.38.
The one-year BDTX stock forecast points to a potential upside of 84.07. The average equity rating for BDTX stock is currently 1.14, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Black Diamond Therapeutics Inc [BDTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BDTX shares is $14.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BDTX stock is a recommendation set at 1.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Black Diamond Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 31, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on July 14, 2023, representing the official price target for Black Diamond Therapeutics Inc stock. Previously, the target price had yet another raise from $2 to $10, while Stifel kept a Buy rating on BDTX stock.
The Average True Range (ATR) for Black Diamond Therapeutics Inc is set at 0.20 The Price to Book ratio for the last quarter was 1.34, with the Price to Cash per share for the same quarter was set at 1.99.
BDTX Stock Performance Analysis:
Black Diamond Therapeutics Inc [BDTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.00. With this latest performance, BDTX shares dropped by -5.33% in over the last four-week period, additionally sinking by -59.12% over the last 6 months – not to mention a drop of -23.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BDTX stock in for the last two-week period is set at 49.90, with the RSI for the last a single of trading hit 56.27, and the three-weeks RSI is set at 45.65 for Black Diamond Therapeutics Inc [BDTX]. The present Moving Average for the last 50 days of trading for this stock 2.5400, while it was recorded at 2.1000 for the last single week of trading, and 4.4700 for the last 200 days.
Insight into Black Diamond Therapeutics Inc Fundamentals:
Black Diamond Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.55 and a Current Ratio set at 5.55.
Black Diamond Therapeutics Inc [BDTX] Institutonal Ownership Details
There are presently around $98.74%, or 101.05%% of BDTX stock, in the hands of institutional investors. The top three institutional holders of BDTX stocks are: T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with ownership of 10.66 million shares, which is approximately 20.5751%. BELLEVUE GROUP AG, holding 8.52 million shares of the stock with an approximate value of $$39.69 million in BDTX stocks shares; and BELLEVUE GROUP AG, currently with $$20.73 million in BDTX stock with ownership which is approximately 8.5869%.
